

Effects of COVID-19 “Sheltering in Place” on Activity in People With Multiple Sclerosis

Valerie J. Block, PT, DPTSc,* Riley Bove, MD, MMSc,* Jeffrey M. Gelfand, MD, MAS, and Bruce A.C. Cree, MD, PhD, MAS

Correspondence

Dr. Cree
Bruce.Cree@ucsf.edu

Neurology: Clinical Practice April 2021 vol. 11 no. 2 e216-e218 doi:10.1212/CPJ.0000000000000982

People with neurologic conditions that impair mobility such as multiple sclerosis (MS) have low levels of physical activity, with walking as their primary form of exercise.^{1–3} When the San Francisco Bay Area shelter-in-place order was announced in mid-March 2020 to flatten the curve of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, the abrupt closure of gyms, fitness studios, and malls greatly limited options for safe exercise. We leveraged an ongoing study using wearable technology to understand the impact of the shelter-in-place policy on physical activity in people with MS (PwMS) at risk for neurologic worsening.

Methods

Average daily step count (STEPS) was measured from a previously detailed UCSF MS Center cohort of PwMS using a wrist-worn accelerometer (Fitbit® Flex2).³ STEPS before and after the shelter-in-place order were available for 42 participants. Amount, type and frequency of exercise, walking score (a proxy for socioeconomic status [SES] via accessibility of amenities and neighborhood density),⁴ and fatigue (Modified Fatigue Index [MFIS-5]) and mental health symptoms (Mental Health Inventory [MHI-5]) were assessed via a questionnaire.³ The UCSF Institutional Review Board approved the protocol. Descriptive statistics and pre-post comparisons were performed using R studio.

Results

In the 42 adult PwMS, the average age was 53.3 (SD 13.0) and the median Expanded Disability Status Scale (EDSS) was 4.0 (3.5–5.5). At baseline, they reported an average of 3 h/wk of exercise, with “outdoor walking” as the primary form of activity in 28 (66.7%). Median STEPS were 5,106 (2,928–7,572) during February and early March 2020 and dropped to 4,180 (1,720–7,411) between March 16, 2020, and April 7, 2020 (a decline in STEPS of 800 is generally considered clinically meaningful).⁵ STEPS decreased in the week ($p = 0.024$) and month ($p = 0.048$) after shelter-in-place vs corresponding time periods before (Wilcoxon signed-rank; figure, A and B). By 3 weeks after March 16, 2020, 43.2% had not recovered to within 10% of their preorder activity level. However, the apparent rebound in STEPS from the week directly after shelter-in-place compared with the third week after shelter-in-place was not significant across the entire group ($p = 0.888$). People who did not recover activity had lower baseline STEPS (3,404 [IQR: 2,136–5,470]) compared with those who rebounded (5,911 [IQR: 2,774–8,263]).

PRACTICAL IMPLICATIONS

Wrist-worn activity monitors can capture in real-time the ecological impact of environmental perturbations on physical activity.

Biosensing technologies could play a crucial role aiding providers to intervene and prevent clinical decline in neurologically vulnerable populations.

MORE ONLINE

COVID-19 Resources

For the latest articles, invited commentaries, and blogs from physicians around the world

[NPub.org/COVID19](https://www.npub.org/COVID19)


*These authors contributed equally to this work.

Department of Neurology, Weill Institute for Neurosciences, MS and Neuroinflammation Clinic, University of California San Francisco.

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/cp](https://www.neurology.org/cp).

Coinvestigators are listed at links.lww.com/CPJ/A217.

Figure Average Daily Step Count (STEPS) Before and After Various Time Points in 2019 and 2020



(A) Decline in STEPS in the week following the shelter-in-place order (March 16, 2020) relative to the week prior and the corresponding periods for 2019. (B) STEPS between February 1 and April 7, 2020. Dashed red line represents shelter-in-place order (March 16, 2020). *Significant difference with the prior time point. 2020 boxplots are represented in a darker shade to the 2019 boxplots for contrast.

Correlations between STEPS change (absolute drop and stable/increase) with age, sex, walking score, MFIS-5, MHI-5, and EDSS were not observed (linear regression). By comparison, for the same epochs in 2019, STEPS remained stable in the week after relative to the week before March 16 (figure A), for the 27 participants with available data. This suggests that seasonal or other patterns were unlikely to influence the 2020 observations.

Discussion

Our continuously obtained, patient-generated data demonstrate a sharp, clinically meaningful decline in physical activity after the SARS-CoV-2-related shelter-in-place from which almost half of patients had not recovered previous activity levels by 1 month.

Periods of lower physical activity have the potential to affect PwMS in several ways. First, sedentarism could lead to further muscular and cardiovascular deconditioning.⁶ Second, low activity levels can also worsen other MS-related symptoms, including depression, fatigue,⁷ and spasticity,⁸ contributing to a further cycle of worsening in function. These observations are not unique to PwMS, and many patients with other forms of chronic neurologic disability display low levels of physical activity and increased sedentarism.

Although many participants were able to return to near-baseline physical activity, almost half did not. Those who did rebound in ambulatory activity levels might have experienced greater resilience in adapting to home exercise programs or walking under new physical distancing rules or enjoyed greater time for activity because of reductions in time commuting to work. Those who did not rebound also had lower baseline activity and are more vulnerable to disability progression.³ This highlights the importance of expanding access to telehealth strategies to promote physical activity.

Study limitations include the potential for reactivity, i.e., that knowledge of being monitored increases activity; however,

this was not seen in our broader study.³ Generalizability to the broader MS population may be limited because of the study design that block recruited by disability³ or because of regional weather or activity patterns. The activity changes observed, although perhaps not specific to MS, have important implications for disability progression in PwMS with baseline limited activity. Because the walking score is an indirect measure of SES, additional measures of SES, among other social determinants of health, could enhance the understanding of their influence on STEPS.

The shelter-in-place order in response to the SARS-CoV2 pandemic offered a natural experiment, showing that wrist-worn activity monitors capture the real-time, real-world impact of ecological perturbations. This study also showed differential ability of patients to respond to such challenges; future evaluations would benefit from focusing more granularly on factors promoting resilience. As biosensor technologies become further integrated into clinical care, this technology could play an important role in clinical responses to such changes, targeting telehealth strategies to increase physical activity and prevent functional decline in neurologically vulnerable populations.

Study Funding

No targeted funding reported.

Disclosure

V.J. Block reports no disclosures. V.J. Block is supported by National MS Society Postdoctoral Fellowship FG-1707-28624. R. Bove is supported by a National Multiple Sclerosis Society Harry Weaver Scholarship Award. She has received research support from the National Multiple Sclerosis Society, the Hilton Foundation, the California Initiative to Advance Precision Medicine, the Sherak Foundation, and Akili Interactive. R. Bove has also received personal compensation for consulting from Alexion, Biogen, EMD Serono, Novartis, Sanofi Genzyme, Roche Genentech, and Pear Therapeutics. J.M. Gelfand reports research support to UCSF from Genentech for a clinical trial and consulting for Biogen and

Alexion. B.A.C. Cree reports receiving personal compensation for consulting from: Akili, Alexion, Atara, Biogen, EMD Serono, Novartis Sanofi, and TG Therapeutics. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/cp](https://www.neurology.org/cp).

Publication History

Received by *Neurology: Clinical Practice* May 15, 2020. Accepted in final form August 25, 2020.

Appendix Authors

Name	Location	Contribution
Valerie J. Block, PT, DPTSc	Department of Neurology, University of California San Francisco	Designed and conceptualized the study, analyzed the data, and drafted the manuscript for intellectual content
Riley Bove, MD, MMSc	Department of Neurology, University of California San Francisco	Designed and conceptualized the study and revised the manuscript for intellectual content
Jeffrey M. Gelfand, MD, MAS	Department of Neurology, University of California San Francisco	Designed and conceptualized the study, interpreted the data, and revised the manuscript for intellectual content

Appendix (continued)

Name	Location	Contribution
Bruce A.C. Cree, MD, PhD, MAS	Department of Neurology, University of California San Francisco	Designed and conceptualized the study, interpreted the data, and revised the manuscript for intellectual content

References

1. Klaren RE, Motl RW, Dlugonski D, Sandroff BM, Pilutti LA. Objectively quantified physical activity in persons with multiple sclerosis. *Arch Phys Med Rehabil* 2013;94:2342–2348.
2. Dlugonski D, Pilutti LA, Sandroff BM, Suh Y, Balantrapu S, Motl RW. Steps per day among persons with multiple sclerosis: variation by demographic, clinical, and device characteristics. *Arch Phys Med Rehabil* 2013;94:1534–1539.
3. Block VJ, Bove R, Zhao C, et al. Association of continuous assessment of step count by remote monitoring with disability progression among adults with multiple sclerosis. *JAMA Netw Open* 2019;2:e190570.
4. Carr LJ, Dunsiger SI, Marcus BH. Walk score™ as a global estimate of neighborhood walkability. *Am J Prev Med* 2010;39:460–463.
5. Motl RW, Pilutti LA, Learmonth YC, Goldman MD, Brown T. Clinical importance of steps taken per day among persons with multiple sclerosis. *PLoS One* 2013;8:e73247.
6. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet* 2012;380:219–229.
7. Hubbard EA, Motl RW. Sedentary behavior is associated with disability status and walking performance, but not cognitive function, in multiple sclerosis. *Appl Physiol Nutr Metab* 2014;40:203–206.
8. White LJ, Dressendorfer RH. Exercise and multiple sclerosis. *Sports Med* 2004;34:1077–1100.

Neurology® Clinical Practice

Effects of COVID-19 "Sheltering in Place" on Activity in People With Multiple Sclerosis

Valerie J. Block, Riley Bove, Jeffrey M. Gelfand, et al.

Neurol Clin Pract 2021;11:e216-e218 Published Online before print September 28, 2020
DOI 10.1212/CPJ.0000000000000982

This information is current as of September 28, 2020

Updated Information & Services	including high resolution figures, can be found at: http://cp.neurology.org/content/11/2/e216.full.html
References	This article cites 8 articles, 0 of which you can access for free at: http://cp.neurology.org/content/11/2/e216.full.html##ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://cp.neurology.org/content/11/2/e216.full.html##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Rehabilitation http://cp.neurology.org/cgi/collection/all_rehabilitation COVID-19 http://cp.neurology.org/cgi/collection/covid_19 Multiple sclerosis http://cp.neurology.org/cgi/collection/multiple_sclerosis
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://cp.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://cp.neurology.org/misc/addir.xhtml#reprintsus

Neurol Clin Pract is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2020 American Academy of Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.

